The Judith and Stewart Colton Center for Autoimmunity at NYU Langone has approved seven new pilot projects for 2019 funding, adding to a portfolio of nearly 20 interdisciplinary collaborations already underway. Published in NYU Langone’s 2018 Rheumatology Year in Review, the article highlights both the new grants and the progress of earlier Colton-funded projects that are advancing through the translational pipeline.
Among the newly funded projects, one team from the Skirball Institute — led by Professors Steven Burden, Damian Ekiert, and Gira Bhabha — is investigating the autoantibodies responsible for myasthenia gravis, with the goal of developing a decoy target that could neutralize them and restore normal nerve-to-muscle signaling. A second project, led by Dr. Theresa Wampler Muskardin, is using blood-based biomarkers — specifically type 1 interferon levels — to predict which rheumatoid arthritis patients are likely to respond to TNF inhibitor therapy, addressing a significant gap in clinical decision-making. A third, led by Dr. Timothy Niewold in collaboration with Professor Jef Boeke, is using synthetic chromosome technology to isolate and study individual gene regions linked to lupus risk, mapping the origins of autoimmune disease with unprecedented precision.
Two earlier Colton-funded projects are also showing translational momentum. Professor Boris Reizis is advancing DNASE1L3 enzyme replacement as a potential lupus therapy, while Professor Gregg Silverman is developing a blood test based on gut microbiome antibodies to predict lupus nephritis.
Together, the projects reflect the Colton Center’s model: seed high-risk, high-reward ideas and shepherd them toward clinical impact.
Featured Experts
Sara Baier, MEd
Associate Director of External Relations, Colton Consortium for Autoimmunity
Colton Center for Autoimmunity, Perelman School of Medicine, University of Pennsylvania
Jennifer Gillen, MBA
Administrative Manager, Judith & Stewart Colton Center for Autoimmunity (NYU)
Department of Medicine, NYU Grossman School of Medicine / NYU Langone Health, New York University
Kenneth Hassinger
Director of Finance, Colton Consortium for Autoimmunity
Colton Center for Autoimmunity, Perelman School of Medicine, University of PennsylvaniaFeatured Projects
Novel Tools to Track and Manipulate Immune Cells in Autoimmunity Models
Developing a cell-labeling tool to map immune cell interactions in living tissue, this project identifies the drivers of skin-resident T cell persistence in psoriasis and potential targets for disease prevention.
Early Detection and Diagnosis of Autoimmune Diseases Using Foundation AI Models
Applying self-supervised AI to multi-modal electronic health records — integrating clinical notes, labs, and imaging — this project builds scalable diagnostic models to detect autoimmune diseases earlier and more precisely.
Related News
A Growing Network Takes Stock: Highlights from the 2026 Colton Consortium Symposium
Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.
$5M Gift Establishes Colton Center for Autoimmunity at Mount Sinai to Advance Precision Medicine for Autoimmune Diseases
A $5 million gift from Judith and Stewart Colton establishes a Colton Center for Autoimmunity at Mount Sinai, expanding the Colton Consortium and advancing precision, early-detection approaches to autoimmune disease research.
What a "Silenced" Chromosome Can Tell Us About Autoimmunity
Penn Colton Center researcher Montserrat Anguera reveals how B cells maintain X chromosome inactivation, and how its breakdown drives lupus, offering new insight into female-biased autoimmune disease and treatment targets.